The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
Abstract
RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A randomised, double-blind, cross-over, placebo controlled trial was conducted in 16 healthy male subjects. Oral THC 10 mg or CBD 600 mg or placebo was administered in three consecutive sessions, at one-month interval. Physiological measures and symptom ratings were assessed before, and at 1, 2 and 3 hours post drug administration. The area under the curve (AUC) between baseline and 3 hours, and the maximum absolute change from baseline at 2 hours were analysed by one-way repeated measures analysis of variance, with drug condition (THC or CBD or placebo) as the factor. RESULTS: Relative to both placebo and CBD, administration of THC was associated with anxiety, dysphoria, positive psychotic symptoms, physical and mental sedation, subjective intoxication (AUC and effect at 2 hours: p < 0.01), an increase in heart rate (p < 0.05). There were no differences between CBD and placebo on any symptomatic, physiological variable. CONCLUSIONS: In healthy volunteers, THC has marked acute behavioural and physiological effects, whereas CBD has proven to be safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“The acute administration of THC is associated with relaxation and enjoyment, but can also lead to unpleasant effects such as anxiety, psychotic symptoms, depression, apathy, and impairment of memory [8].”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024
Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“Although studies in both experimental animals [73-77] and healthy volunteers [18, 29, 34, 49,78,79] have shown that CBD has anxiolytic properties, there were remarkably few differences between the effects of CBD and placebo on anxiety [17], save for a reduction in the VAMS anxiety scale at 2 hours post administration.”
BackgroundSelf-citationIversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Self-citationRusso, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Self-citationSafety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 2×
“CBD is pharmacologically active and can have anticonvulsant, sedative, anxiolytic [3,4,17,18] and antipsychotic effects [4, 19-25].”
BackgroundResultCrippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Self-citationReliability, validity, and clinical application of the visual analogue mood scale
Folstein, M. F., & Luria, R. (1973) · Psychological Medicine · doi:10.1017/s0033291700054283 · Cited by 514
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
Self-citationCarrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Self-citationCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 2×
“CBD is pharmacologically active and can have anticonvulsant, sedative, anxiolytic [3,4,17,18] and antipsychotic effects [4, 19-25].”
BackgroundCannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Self-citationAntianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 2×
“Although studies in both experimental animals [73-77] and healthy volunteers [18, 29, 34, 49,78,79] have shown that CBD has anxiolytic properties, there were remarkably few differences between the effects of CBD and placebo on anxiety [17], save for a reduction in the VAMS anxiety scale at 2 hours post administration.”
BackgroundCurran, V., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1169-0 · Cited by 369
Effects of THC on Behavioral Measures of Impulsivity in Humans
McDonald, J., Schleifer, L., Richards, J. B., & de Wit, H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300176 · Cited by 368
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
Gaoni, Y., & Mechoulam, R. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00730a036 · Cited by 364
Cardiovascular System Effects of Marijuana
Jones, R. T. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb06004.x · Cited by 319
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 311
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307
Self-citationCannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 305
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D., Holt, D. W., Powell, J. F., Kapur, S., & Murray, R. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005522 · Cited by 298
Cannabis and Cognitive Functioning
Solowij, N. (1998) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526824 · Cited by 269
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
Self-citationCannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
Mechoulam, R., & Hanuš, L. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00144-5 · Cited by 250
Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S., & Huestis, M. A. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.152439 · Cited by 231
Comparison of the subjective effects of Δ 9 -tetrahydrocannabinol and marijuana in humans
S., W., M., E., S., R., J., A., & Wit, H. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1033-2 · Cited by 210
Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., & Brenneisen, R. (2003) · Pain · doi:10.1016/s0304-3959(03)00163-5 · Cited by 209
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.011 · Cited by 195
Self-citationCannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192
Self-citationNadulski, T., Pragst, F., Weinberg, G., Roser, P., Schnelle, M., Fronk, E.-M., & Stadelmann, A. M. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000177223.19294.5c · Cited by 185
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol
Karniol, I. G., & Carlini, E. A. (1973) · Psychopharmacologia · doi:10.1007/bf00428793 · Cited by 182
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 161
Self-citationDifferent Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 157
Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.5.283 · Cited by 148
Nadulski, T., Sporkert, F., Schnelle, M., Stadelmann, A. M., Roser, P., Schefter, T., & Pragst, F. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.782 · Cited by 146
Kraft, B., Frickey, N., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., & Kress, H. G. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31817881e1 · Cited by 130
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123
Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.318 · Cited by 117
Bhattacharyya, S., Atakan, Z., Martín‐Santos, R., Crippa, J. A., Kambeitz, J. P., Prata, D. P., Williams, S., Brammer, M. J., Collier, D. A., & McGuire, P. K. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.187 · Cited by 115
Self-citationSoares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112
Self-citationToward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal, J. H., D’Souza, D. C., Madonick, S. H., & Petrakis, I. L. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00162-5 · Cited by 105
Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., & Emrich, H. M. (1999) · Psychopharmacology · doi:10.1007/s002130050884 · Cited by 102 · cited 1×
“The doses of THC and CBD were selected on the basis of previous research [37,54-56] to produce a neurocognitive effect without provoking severe toxic, psychiatric or physical symptoms, which might confound interpretation of physiological and neuro-psychological data, or lead to the subject being unable to co-operate w…”
MethodTwo cases of "cannabis acute psychosis" following the administration of oral cannabis
Favrat, B., Ménétrey, A., Augsburger, M. P., Rothuizen, L. E., Appenzeller, M., Buclin, T., Pin, M. A., Mangin, P. J., & Giroud, C. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-17 · Cited by 100
Cone, E. J., & Huestis, M. A. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199312000-00013 · Cited by 99
Roser, P., Juckel, G., Rentzsch, J., Nadulski, T., Gallinat, J., & Stadelmann, A. M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.008 · Cited by 95
Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93
Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2495-x · Cited by 84
Self-citationCocchetto, D. M., Owens, S. M., Perez‐Reyes, M., Guiseppi, S. R. D., & Miller, L. L. (1981) · Psychopharmacology · doi:10.1007/bf00432179 · Cited by 83
What is the mechanism whereby cannabis use increases risk of psychosis?
Luzi, S., Morrison, P. D., Powell, J. F., Forti, M. D., & Murray, R. M. (2008) · Neurotoxicity Research · doi:10.1007/bf03033802 · Cited by 70
Interaction of cannabidiol and alcohol in humans
Consroe, P. F., Carlini, E. A., Zwicker, A. P., & de Lacerda, L. A. (1979) · Psychopharmacology · doi:10.1007/bf00431988 · Cited by 63
Roser, P., Gallinat, J., Weinberg, G., Juckel, G., Gorynia, I., & Stadelmann, A. M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0868-5 · Cited by 60
The effect of cannabidiol, alone and in combination with ethanol, on human performance
Belgrave, B. E., Bird, K. D., CHESHER, G. B., Jackson, D. M., Lubble, K. E., Starmer, G. A., & Teo, R. K. C. (1979) · Psychopharmacology · doi:10.1007/bf00496070 · Cited by 57
The effects of cannabis on information-processing speed
Kelleher, L. M., Stough, C. K. K., Sergejew, A. A., & Rolfe, T. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.03.039 · Cited by 57
Sewell, R. A., Skosnik, P. D., Stavers-Sosa, I., Ranganathan, M., & D’Souza, D. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500005 · Cited by 56
Kaufmann, R. M., Kraft, B., Frey, R., Winkler, D., Weiszenbichler, S., Bäcker, C., Kasper, S. F., & Kress, H. G. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1237397 · Cited by 41
CHESHER, G. B., Bird, K. D., Jackson, D. M., Perrignon, A., & Starmer, G. A. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90371-n · Cited by 39
Cannabis sativa: a planta que pode produzir efeitos indesejáveis e também tratá-los
Zuardi, A. W., Crippa, J. A. S., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500001 · Cited by 24
Self-citationThe safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans
Sugarman, D. E., Poling, J. C., & Sofuoglu, M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.013 · Cited by 23
Methods for Clinical Research Involving Cannabis Administration
Gorelick, D. A., & Heishman, S. J. (2006) · Humana Press eBooks · doi:10.1385/1-59259-999-0:235 · Cited by 22
Zuardi, A. W., & Karniol, I. G. (1983) · Americanae (AECID Library) · Cited by 18
Self-citation
Cited by
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 433
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00054 · Cited by 310
Metadata
- Authors
- Martin-Santos, R., A. Crippa, J., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M., Langohr, K., Farre, M., Zuardi, A., & K. McGuire, P.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-09-12
- Volume
- 18
- Issue
- 32
- Pages
- 4966-4979
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2149642074
- Cited by
- 295
- References
- 74
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.